IMUX
IMMUNIC, INC.
Key Financials
Revenue
$22000
N/A
Gross Profit
$9000
N/A
Net Income
$-97172000
↑ 3.3%
Operating Income
$-103228000
↓ 5.3%
EPS (Diluted)
$-0.62
↑ 38.0%
Total Assets
$24.1M
↓ 41.1%
Total Liabilities
$30.7M
↑ 36.9%
Shareholders' Equity
$-6673000.00
↓ 136.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| S-8 | 8/12/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 4 | 8/10/2026 | View on SEC |
| 3 | 8/10/2026 | View on SEC |
| SCHEDULE 13G/A | 8/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMUX |
| Company Name | IMMUNIC, INC. |
| CIK | 1280776 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (332) 255-9818 |